Bayer: Nexavar study shows survival boost

Bayer and Onyx Pharmaceuticals are anticipating the release of two new studies of their liver cancer treatment Nexavar; the studies include evidence of extended survival in more than 40 percent of patients and identification of biomarkers that might predict success with Nexavar therapy. Release

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.